Lantheus Medical Imaging said this week it brokered a deal to distribute its Definity contrast material for echocardiograms in China.
Lantheus and Beijing Double-Crane Pharmaceutical Co., a leading drug company in Beijing, approved a 15-year agreement for exclusive distribution in China pending clinical trials, according to a company press release.
Under the agreement, both companies will collaborate on designing and implementing the drug trials. Double-Crane also has the right of first negotiation to manufacture the injectable drug used to treat heart disease.
Definity is currently approved in North America, Europe and a number of other countries.